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ABSTRACT
Objectives To evaluate the psychometric properties 
(and identify specific anomalies to be resolved) of urinary 
and sexual function scales of the Symptom Tracking and 
Reporting (STAR) instrument for use in clinical practice 
with individual men using Rasch analysis.
Design Prospective cohort study.
Setting 9 UK surgery centres in secondary care.
Participants 403 men diagnosed with prostate cancer 
and completed at least one questionnaire immediately 
before and at 1 or 3 months after radical prostatectomy.
Primary and secondary outcomes STAR instrument 
before surgery and 1 and 3 months afterwards.
Results Neither scale fitted the Rasch model (both scales 
p<0.001). Both urinary (seven items) and sexual function 
(six items) had disordered thresholds, suggesting response 
categories are not working as intended. Both scales 
(three urinary items; five sexual function items) showed 
problems with item fit (large fit residuals, significant χ2, 
an inspection of item characteristic curves). Both scales 
showed items that were unstable over time (differential 
item functioning (DIF) by time). Both scales (four pairs of 
items in each scale) showed local response dependency 
(residual correlations >0.2 above the average). Internal 
consistency was acceptable at the group level for both 
scales. Targeting was poor for both scales, indicating an 
inadequate match between the location of items and the 
distribution of the patients, suggesting that the underlying 
constructs that the scales purport to measure are not clear.
Conclusion Using Rasch analysis as a diagnostic tool, 
we identified that both the urinary and the sexual function 
scales have issues that need to be resolved before STAR 
can be used with confidence in clinical practice. The 
sexual function scale, in particular, is unlikely to provide 
precise estimates for the outcomes experienced by men 
after radical prostatectomy. These results demonstrate 
the need to evaluate the suitability of any patient- reported 
outcome measure before implementation in routine clinical 
practice, preferably using modern psychometric methods.
INTRODUCTION
The use of patient- reported outcome 
measures (PROMs) has rapidly increased.1–3 
In the UK, PROMs are routinely collected for 
several areas of elective surgery to evaluate 
the outcomes in groups of patients, receiving a 
particular treatment or treated in a specific 
hospital.4 5 Similar approaches are under 
consideration for other conditions.
However, there is a lack of evidence about 
the extent to which clinicians can use PROMs 
to make their clinical practice more respon-
sive to individual patients’ needs. Also, it has 
been suggested that PROMs can play an 
important role for patients as they can help 
to inform ways in which patients can self- 
manage their condition.6 7
A web- based tool known as Symptom 
Tracking and Reporting (STAR)8 has been 
developed at the Memorial Sloan- Kettering 
Cancer Center (New York, USA) to monitor 
outcomes of radical prostate cancer treatment 
in individual patients. This instrument is used 
to inform both surgeons and men about func-
tional outcomes after surgery, such as urinary, 
sexual and bowel function improvement or 
deterioration. Its development is just one 
example of the implementation of PROMs in 
prostate cancer practice to inform both clini-
cians and patients.9–11
The STAR instrument was not designed 
to compare men’s functional status before 
and after surgery because different ques-
tions are included in the pre- treatment and 
Strengths and limitations of this study
 ► Used modern psychometric methods (based on 
Rasch measurement theory) to determine if it is ap-
propriate to use a total function score to describe a 
patient’s sexual or urinary function.
 ► Determined how well the items in each scale reflect 
the experience of men who report the questionnaire.
 ► Determined specific anomalies in the scores that 
suggest that the scales are not being used and un-
derstood in the way that was intended.
 ► Did not change the items in the questionnaire based 
on our findings and so did not evaluate any potential 
improvement such changes would make. copyright.
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post- treatment STAR questionnaires. This means that 
the assessment before surgery is on a different ‘ruler’ 
compared with after surgery and therefore there is no 
clear way of understanding what the change means. 
However in practice, for example in the English national 
PROMs programme, pre- treatment and post- treatment 
PROMs are often compared to monitor the impact of 
elective surgery.2
Instruments such as STAR aim to measure specific 
‘constructs’. It is important these instruments have 
adequate psychometric properties, otherwise they may 
produce scores that are ‘inaccurate’ (prone to systematic 
error) or ‘imprecise’ (prone to random error), making 
it difficult to understand what the observed scores mean 
and even more difficult to interpret changes over time.
The criteria that must be met to ensure that PROMs 
are robust are well established.12–15 They ensure that the 
‘scale’ that results from adding up responses to individual 
questions (items) relates to a clear underlying construct, 
as distinct from descriptive responses or simple counts of 
how many times a symptom occurs.
Like most health- related PROMs, the STAR instru-
ment has been developed using traditional psychometric 
methods based on classical test theory (CTT). There are 
important limitations to these methods.16 First, the scales 
developed using CTT produce ‘ordinal scores’, where 
the difference between two adjacent scores at different 
points on the scale may not be equal. This poses a 
problem because most statistical analyses assume scores 
have interval properties where differences between adja-
cent scores are equal across the entire scale. When scales 
are based on ordinal scores, changes over time are espe-
cially difficult to interpret. Second, the scores can only be 
interpreted for groups of patients, because measures of 
statistical uncertainty of these scores (eg, ‘SEs’) are only 
computed at the group level, which limits their use for 
individual patients.17 Third, the performance of scales 
is dependent on the particular sample in which they are 
used. This makes it difficult to compare studies and, even 
more importantly, undermines further the interpretation 
of changes over time.
Modern psychometric methods, such as those based 
on ‘item response theory’ (IRT) or ‘Rasch measurement 
theory’, provide a way of overcoming these challenges. 
Both are mathematical modelling approaches trans-
forming ordinal scales into interval measures, provided 
that certain model- related criteria are met. But whereas 
IRT takes a statistical approach of adding parameters to 
the model in order to improve its fit to the data, the Rasch 
paradigm takes a theory- driven approach that investigates 
why the data do not fit the Rasch model.18–20 The Rasch 
paradigm keeps central the conceptual underpinning 
of the instrument and provides a clear set of diagnostic 
statistics that can help to identify anomalies in its scores.
Instruments developed using these modern psycho-
metric methods have four main advantages over CTT- 
based instruments. First, they have the potential to 
generate truly interval scores, thus improving the accuracy 
and precision with which change over time can be evalu-
ated. Second, measures of statistical uncertainty can be 
estimated for scores of individual respondents, meaning 
that the interpretation of scores at the patient level is 
more meaningful. Third, it is possible to produce scales 
that do not depend on a particular sample’s characteris-
tics. Fourth, they can create a model that contains both 
presurgery and postsurgery items, and therefore all items 
can be calibrated on the same ruler. The usual pretreat-
ment and post- treatment scores can still be derived 
but calibrated in such a way that they can be properly 
compared.
In a systematic review of seven prostate cancer- specific 
PROMs, including the STAR instrument,21 we identified 
that modern psychometric methods had not been used 
to evaluate the psychometric properties of these instru-
ments. In this study, we therefore used Rasch analysis to 
estimate urinary and sexual function for individual men 
based on responses to the STAR instrument that were 
provided by men immediately before and up to 3 months 
after radical prostate cancer surgery. In so doing, we 
aimed to identify anomalies that should be addressed to 
make the STAR instrument, or any other PROM that aims 
to monitor changes in outcomes over time after prostate 
cancer surgery, suitable for use in routine clinical practice.
We performed analyses based on Rasch measurement 
theory to determine if it is appropriate to use a total func-
tion score to describe a patient’s sexual or urinary func-
tion. As comparisons are often made between pre- surgery 
and post- surgery scores, we aimed to determine if the 
seven pre- surgery and five post- surgery- items could be 
placed on the same measurement ruler. If they can, then 
meaningful comparisons can be made across time. To do 
this, we ‘stacked’ the data, in other words, we added the 
baseline and follow- up scores for each patient as separate 
records.22
The analyses aimed to answer a number of ques-
tions. First, has a measurement ruler been successfully 
constructed? Second, have the people been success-
fully measured? Third, is the scale- to- sample targeting 
adequate? The approach to each of these questions is 
explained briefly below. A more extensive explanation 
of Rasch measurement theory can be found in recent 
overviews.23
METHODS
Setting and participants
Participants were recruited between November 2015 and 
March 2017 from nine centres that perform radical pros-
tatectomy by any method (open, laparoscopic- assisted 
or robotic- assisted) in the UK. Men were eligible if 
they were diagnosed with prostate cancer, scheduled to 
have a radical prostatectomy and had sufficient English 
language to understand the information about the study 
and complete the required online questionnaire.
The clinical team at each centre identified and 
approached eligible patients, informed them about the 
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study, and registered those who were interested in taking 
part on the secure online portal. Registered patients 
received their login details by text or email and logged on 
to the portal to complete the consent form. Once patients 
had consented, they were directed to the online question-
naire. Patients were invited to complete the questionnaire 
before surgery, and at 1, 3, 6 and 12 months after surgery.
Instrument
The STAR instrument consists of four domains: sexual 
function, urinary function, bowel function and overall 
quality of life. Our analysis focused on the urinary and 
sexual function scales obtained immediately before and 1 
and 3 months after surgery. We excluded the bowel scale 
from psychometric analyses as with only two items it had 
insufficient content to be considered a scale. Likewise, 
the single- item scale for overall quality of life was not 
considered in our analysis.
Urinary and sexual function items are scored on 3- point 
to 11- point Likert scales. The pre- surgery form of the 
STAR instrument includes seven urinary function items 
and the post- surgery form includes five (questions 2 and 
4 are common to both). For sexual function, the same 
six items are included in both presurgery and postsur-
gery forms. Item scores are summed for the urinary and 
sexual function domains and then transformed to scores 
ranging from 0 to 100.
We made two wording changes to the STAR instrument. 
First, our data collection also included the Expanded 
Prostate Cancer Index Composite (EPIC)-26 question-
naire (not reported in the present paper) which overlaps 
with some STAR items. Where an item existed in both 
questionnaires, we used the EPIC wording. These minor 
wording changes are unlikely to substantially change the 
performance of the item. Second, the standard updated 
version of STAR has a time frame of 6 months preopera-
tively for both sexual and urinary function, 4 weeks post-
operatively for sexual function and 1 week postoperatively 
for urinary function. To ensure consistency across time 
for both urinary and sexual function domains, we used a 
4- week recall period throughout. We considered this long 
enough for all problems to be noticed and/or resolved. 
All items were administered at all time points.
Data analysis
Overall fit to the model
For each scale, we evaluated whether the observed 
responses were significantly different from the responses 
expected based on the Rasch model (significant χ2 
statistic).
Item threshold ordering
For a higher level of functioning on each item, the prob-
ability of ‘endorsing’ a higher response category (on 
the Likert scale) should increase and the probability of 
endorsing a lower response category decrease. If each 
response category in turn (0, 1, 2, 3, 4, 5) has the highest 
probability of endorsement with increasing levels of 
functioning, the ‘thresholds’ between the categories (0–1, 
1–2, 2–3, 3–4, 4–5) show a logical order. Thresholds are 
the location on the scale where the two adjacent response 
categories have equal probability (50%) of endorsement.
Empirically, however, thresholds can be disordered (eg, 
0–1, 2–3, 1–2), indicating that the response categories do 
not work as intended. This can be because an item has 
ambiguous wording or has labels on the response scale 
that are not sufficiently distinct. We evaluated whether 
the response categories are working as intended by visual 
inspection of the ‘category probability curves’.
Item fit validity
The items of the scale must work together (fit) as a 
conformable set both clinically and statistically. Clinically, 
the item ordering along the continuum should make 
sense and statistically, the items need to satisfy speci-
fied criteria. Otherwise, it is inappropriate to sum item 
responses to reach a total score and consider the total 
score as a measure of the construct. When items do not 
work together (‘misfit’) in this way, the validity of a scale 
needs to be questioned.
We evaluated the fit of each item to the Rasch model by 
inspecting its ‘fit residual’ (acceptable range of ±2.5) and 
considering the related χ2 value. We also assessed visu-
ally how closely the observed ‘class interval mean scores’ 
follow the expected values in the ‘item characteristic 
curve’. Class intervals are groupings of approximately 
equal numbers of respondents who have about the same 
level of functioning.
Differential item functioning
Stability of the item locations is assessed by evaluating 
differential item functioning (‘DIF’). DIF occurs when 
different groups within the sample, for example patients 
of different age, respond differently to an item, despite 
having the same level of functioning. DIF is identified 
through an analysis of variance (ANOVA) main effect 
for ‘person factors’, for example age by an interaction 
between the person factor and the class intervals.
In both the urinary and sexual function scales, we evalu-
ated DIF by age, ethnicity, relationship status and number 
of comorbidities. For items that were scored both before 
and after surgery (two items for the urinary function scale 
and all six items for the sexual functioning scale), we also 
evaluated DIF by time point.
Local response dependency
The response to one item should not directly influence 
the response to another. If ‘item response- dependency’ 
happens, measurement estimates can be biased, and 
reliability, indicated by the ‘person separation index’, is 
artificially increased. Local response dependency is eval-
uated by examining the residual correlations between 
the items after the Rasch factor they have in common 
has been partialled out. A correlation coefficient with a 
value larger than 0.20 above the average of all the item 
copyright.
 on D
ecem
ber 6, 2020 at LS
H
T
M
 C
onsortia. P
rotected by
http://bm
jopen.bm
j.com
/
B
M
J O
pen: first published as 10.1136/bm
jopen-2019-035436 on 14 N
ovem
ber 2020. D
ow
nloaded from
 
4 Protopapa E, et al. BMJ Open 2020;10:e035436. doi:10.1136/bmjopen-2019-035436
Open access 
residual correlations indicates potential local response 
dependency.24
Reliability (internal consistency)
Reliability was examined using the ‘person separation 
index’ which is a statistic comparable to the Cronbach’s 
alpha, often used in traditional methods based on CTT. 
It quantifies how reliably the scale distinguishes between 
respondents. It is computed from the variation among 
person locations relative to the SE of estimate for each 
individual respondent.16 Higher person separation index 
values indicate better reliability; a value >0.70 at group 
level and >0.85 at individual level indicates adequate 
reliability.20
Scale to sample targeting
‘Scale- to- sample targeting’ describes the match between 
the range of the construct measured by the items and 
the range of the construct in the sample of patients. 
This is evaluated by the ‘person- item distribution’ which 
compares the difference between ‘person locations’ and 
‘item threshold locations’ on the underlying ruler, that 
captures for example urinary or sexual function. Any 
gaps in item threshold locations, in particular at the low 
and high ends of the scale, means that the functioning of 
respondents located in that gap area cannot be measured 
precisely. In other words, their scores will have a relatively 
large SE of measurement, because their estimation is 
severely affected by missing information.
All p values were adjusted for sample size (n=500) as χ2 
values are sensitive to sample size.25 As a sensitivity analysis 
for the correction of the p values, we repeated all analyses 
on a random subsample of 400. Furthermore, Bonferroni 
corrections for multiple testing were also applied. All 
analyses were carried using RUMM 2030.26
Patient and public involvement statement
Patients and the public were not involved in the design, 
conduct or dissemination of the project, except as partic-
ipants in the study.
RESULTS
Study sample
Overall, 971 men were eligible, of whom 873 were 
approached, 714 were interested and 431 men completed 
the online consent form, giving an overall recruitment 
rate of 44.4%.
Of the 431 patients who provided consent, 403 patients 
(93.5%) completed at least one valid questionnaire. A 
total of 366 valid questionnaires were completed at base-
line, 222 questionnaires were completed at 1 month after 
surgery and 181 questionnaires at 3 months after surgery. 
Table 1 describes the characteristics of the 403 patients 
included in this analysis. These patients had a mean age 
of 63 years (SD 6.7; range 41–78 years), were predomi-
nantly white or white British (79.7%), and were mostly 
married or living with a partner (76.7%).
Overall fit to the model
The overall χ2 statistic indicated that neither the urinary 
function nor the sexual function scale fit the Rasch model 
(urinary function, χ2=207.04; p<0.001; sexual function, 
χ2=341.98; p<0.001).
Item threshold ordering
Both urinary and sexual function scales had items with 
disordered thresholds, indicating that the response 
options were not working as intended. The urinary 
function scale had disordered thresholds for 7 of the 
10 items. For these seven disordered items, the cate-
gory probability plots in figure 1A–G illustrate that this 
is mainly a problem with the middle response options, 
suggesting that the wording was not clear or that the 
difference between categories was not well understood. 
For example, for Q3 of the urinary function scale (over 
the last 4 weeks, how often have you found you stopped 
and started again several times when you urinated?) there 
is no point at which threshold 2 (about half the time) 
and threshold 3 (less than half the time) are the most 
likely to occur. If the response options were working as 
intended, the probability of each threshold should come 
in order.
All six of the sexual function items are disordered. 
This means that none of the response scales are 
working as they were intended. Figure 2A–F indicates 
that it is mainly thresholds 2 and 3 that are disordered, 
suggesting that the middle categories of the response 
scales are not well understood and may need to be 
reworded.
Table 1 Sample characteristics of the 403 patients who 
completed at least one valid questionnaire
Sample characteristics N (%)
Age (years)
  <60 123 (30.5)
  60–66 131 (32.5)
  >66 149 (37.0)
Ethnicity
  White/white British 321 (79.6)
  Other ethnicity 45 (11.2)
  Missing 37 (9.2)
Relationship
  Married or living with a partner 309 (76.7)
  Other 55 (13.6)
  Missing 39 (9.7)
No. of comorbidities
  0 133 (33.0)
  1 164 (40.7)
  >2 69 (17.1)
  Missing 37 (9.2)
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Item fit validity
Both the urinary and sexual function scales contained 
items that did not fit the model, when considering 
together their fit residual, χ2 value, and the item charac-
teristic curve (fit residuals and chi2 values for all items are 
reported in table 2). One urinary function item (Q23) 
failed all three criteria indicating misfit to the model. Two 
further items failed one or two criteria (Q3 and Q7) indi-
cating a broader problem with item fit.
Five sexual function items failed all three criteria 
(table 2) and the remaining item failed one of the three 
criteria suggesting further problems with item fit.
Differential item functioning
Overall, items in both scales were stable (invariant) across 
different groups for age, ethnicity, relationship status and 
number of co- morbidities. However, both scales contained 
items that were unstable across time, with the sexual func-
tion scale containing a greater number of unstable items.
One urinary item (Q23) showed DIF across time points 
(p<0.001). Patients’ response to this item were systemati-
cally higher at 3 months post- op compared with 1 month 
postsurgery, despite having equal underlying levels of 
urinary function.
Five sexual function items (Q9, Q10, Q11, Q12, Q13) 
showed DIF by time (p<0.001)
Local response dependency
Both scales contained pairs of items that were depen-
dent on each other, but the sexual function scale showed 
greater local dependency. Four pairs of urinary function 
items showed local dependency: Q3 (stopped and started 
again) and Q4 (difficulty postponing urination) (residual 
correlation=0.10); Q5 (weak urinary stream) and Q6 
(push or strain to begin urination) (residual correla-
tion=0.04); Q19 (leaking urine) and Q21 (number of 
pads per day) (residual correlation=0.32); Q21 (number 
of pads per day) and Q23 (urinary problem overall) 
(residual correlation=0.13).
Four pairs of sexual function items showed local depen-
dency with relatively high residual correlations: Q10 
(erection during sexual activity) and Q11 (erections hard 
enough for penetration) (residual correlation=0.30), 
Q12 (able to penetrate) and Q13 (maintain erection 
after penetration) (residual correlation=0.59), Q12 (able 
to penetrate) and Q14 (maintain erection to completion) 
(residual correlation=0.55), Q13 (maintain erection after 
Figure 1 (A–G) Urinary function category probability curves for disordered items.
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Figure 2 (A–F) Sexual function category probability curves for disordered items.
Table 2 Urinary function and sexual function—item fit
Location SE Fit residual DF χ2 DF Prob ICC
Urinary function item
Q1 non- complete emptying −0.492 0.05 −3.077 294.8 15.691 8 0.047026
Q2 urinate again less than 2 hours 0.33 0.04 0.21 598.6 6.623 9 0.676341
Q3 stopped and started again −0.329 0.05 −0.591 294 8.401 8 0.39534
Q4 difficult to postpone −0.155 0.03 2.151 595.3 14.137 9 0.117529
Q5 weak stream 0.093 0.05 0.499 294 7.733 8 0.460021
Q6 push/strain to begin −1.103 0.07 −1.731 294.8 6.196 8 0.625333
Q7 get up in night to urinate 0.238 0.05 3.228 295.6 22.219 8 0.004526
Q19 leaked urine 0.908 0.05 −1.496 303.8 7.676 9 0.567147
Q21 pads per day 0.224 0.06 −2.185 304.7 25.356 9 0.002602
Q23 urinary function—problem 0.287 0.05 −3.157 300.5 27.97 9 0.000965 Questionable
Sexual function Item
Q9 confidence to get and keep erection 0.119 0.06 5.814 400.7 135.79 8 0 Questionable
Q10 erection during sexual activity −0.496 0.05 −2.28 399.9 30.792 8 0.000153
Q11 erections hard enough for penetration −0.266 0.05 −3.729 399.1 48.484 8 0 Questionable
Q12 able to penetrate partner 0.195 0.05 −6.208 397.4 49.952 8 0 Questionable
Q13 maintain erection after penetration 0.32 0.05 −5.078 396.6 41.819 8 0.000001 Questionable
Q14 maintain erection to completion 0.129 0.05 −5.152 398.3 35.149 8 0.000025 Questionable
Highlighted items fail criteria.
ICC, item characteristic curve.
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penetration) and Q14 (maintain erection to completion) 
(residual correlation=0.51).
Reliability
Internal consistency was acceptable at group level for 
both scales (urinary function scale: person separation 
index=0.75; sexual function scale: person separation 
index=0.82).
Scale-to-sample targeting
The person- item distribution of the urinary function 
scale was relatively poor, though better than the targeting 
for the sexual function scale (figure 3A). Although the 
middle of the person distribution is reasonably well 
matched by items, both extremes of the distribution have 
few items. This means that for men located at the lower 
end of the scale (including many men at 1 month after 
surgery) and at the higher end of the scale (including 
many men before surgery) the level of functioning cannot 
be precisely measured.
The targeting for the sexual functioning scale was also 
poor (figure 3B). In particular, most items are located in 
the centre of the scale whereas the distribution of people 
is quite wide. This means that the sexual function for men 
located at the higher end of the scale (often men before 
surgery) and the lower end of the scale (most of the men 
after surgery) is very imprecisely measured.
The sensitivity analyses conducted on a random subsa-
mple (n=400) broadly showed a pattern of results that was 
comparable with the whole sample results presented here. 
The targeting diagrams, disordered thresholds, pattern 
of local response dependency and DIF are very similar. 
The pattern of item fit is slightly improved in the random 
subsample and as expected (because the n is smaller) 
fewer items meet the criteria for misfit based on fit resid-
uals and the significance of the chi square. However, the 
pattern of variation across items for misfit is in the same 
direction as the original sample.
DISCUSSION
Our analyses have identified that neither the urinary func-
tion items nor the sexual function items from the STAR 
instrument can be placed on a common metric that is 
robust for comparisons before and after surgery. Further-
more, a number of anomalies have been identified that 
suggest the scales are not working as intended. There 
is an inadequate match between the location of items 
and the distribution of the patients, suggesting that the 
underlying constructs that the scales purport to measure 
are not clear. Consequently, the items do not measure the 
men’s function very accurately. The response categories 
for many items are not consistently used, some items do 
not work with the others as a conformable set and some 
items are not stable over time.
These results indicate that in its current form the items 
in the STAR instrument do not provide an adequate ruler 
to monitor urinary or sexual function in clinical practice. 
These problems are likely to make the estimation of an 
individual patient’s outcome after surgery less accurate 
and precise and using the questionnaire in its current 
form, therefore, carries a risk of misrepresenting actual 
urinary and sexual outcomes.
Our results demonstrate that the risk of inaccurate 
estimation of outcomes using STAR is likely to be most 
pronounced for men with either very good or very poor 
outcomes. The poor scale- to- sample targeting, partic-
ularly for the sexual functioning scale, also means that 
this problem is exacerbated for men with better func-
tion before surgery and worse function after surgery, 
creating clear problems for the interpretation of change 
scores that are supposed to capture the impact of surgery. 
Further, both scales have items that showed DIF by time 
providing further evidence that it is not meaningful to 
compare scores before and after surgery or compare 
scores taken at different times after surgery.
In the short term, some of the identified deficiencies 
can be addressed using post hoc statistical techniques to 
rescore the disordered thresholds16 20 or to resolve for the 
uniform DIF25 and local response dependency.20 However, 
a more robust solution would be to conduct qualitative 
research with men who have experienced radical pros-
tatectomy to understand why the questions are not well 
understood and why the response options are not used 
in the way that was intended. Qualitative research should 
also explore which areas of content are missing and how 
items could be formulated to address these gaps. A revised 
version based on these findings would then need to be 
psychometrically evaluated again to determine how well 
the amendments to content and scoring have addressed 
the identified problems.
Figure 3 (A) Urinary function person- Item distribution 
(targeting). (B) Sexual function person- Item distribution 
(targeting).
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This study is the first to use robust modern psycho-
metric methods such as Rasch analysis to determine the 
measurement properties of a prostate cancer- specific 
PROM21 and to evaluate its suitability to collect PROMs 
for use in clinical practice at the level of individual 
patients. It has allowed us to scrutinise each aspect of 
the questionnaire and to identify carefully which aspects 
work well and which do not.
In our study, the questionnaire was completed at 
home rather than in clinic and there may be differences 
between our setting and the setting that was originally 
used to develop the instrument, especially with respect 
to the amount of support men received while completing 
the questionnaire.
We also used a different time frame and did not adapt 
the questions to UK English (as we wanted to evaluate the 
original questionnaire in its US wording). Yet, it is likely 
that the anomalies identified in relation to item misfit 
and inconsistent threshold ordering reflected ambig-
uous and confusing wording rather than simply linguistic 
differences between the US and UK English.
All of our analyses used a Bonferroni correction to 
adjust the p values. Although widely used, this approach 
has been criticised as conservative. This may therefore 
have had the effect of under- estimating the number of 
anomalies found in these two scales.
CONCLUSION
Using Rasch analysis as a diagnostic tool, we have iden-
tified several shortcomings of the STAR instrument. In 
their current form, both the urinary function and the 
sexual function scales have issues that need to be resolved 
before STAR can be used with confidence in clinical prac-
tice. The sexual function scale, in particular, is unlikely to 
provide precise estimates for the outcomes experienced 
by men after radical prostatectomy. For both scales, 
the underlying construct is not clear and needs further 
investigation.
Our results demonstrate the need to evaluate the 
suitability of any PROMs in routine clinical practice, 
including for example the EPIC-26 that is currently being 
implemented in prostate cancer care in the UK,10 11 using 
modern psychometric methods to identify and address 
deficiencies that affect their psychometric performance.
Without appropriate psychometric scrutiny and related 
further development where needed, the use of PROMs 
in routine clinical practice may significantly misrepre-
sent the true clinical outcomes for patients. PROMs that 
produce inaccurate and imprecise scores have limited 
value for clinicians who aim to respond to the needs of 
their patients. Inaccurate and imprecise scores will also 
undermine the guiding role that PROMs can have for 
patients who want to contribute to the management of 
their own condition. Without progress in development 
in this area, we lose the opportunity to demonstrate the 
benefit of new technology. This will be detrimental to 
patients both now and in the future.
Twitter Caroline M Moore @mrsprostate
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